Diversity of Endophytic Fungal Community in Leaves of Artemisia argyi Based on High-throughput Amplicon Sequencing.

To investigate the community structure and diversity of endophytic fungi in the leaves of Artemisia argyi, leaf samples were collected from five A. argyi varieties grown in different cultivation areas in China, namely, Tangyin Beiai in Henan (BA), Qichun Qiai in Hubei (QA), Wanai in Nanyang in Henan (WA), Haiai in Ningbo in Zhejiang (HA), and Anguo Qiai in Anguo in Hebei (AQA), and analyzed using Illumina high-throughput sequencing technology. A total of 365,919 pairs of reads were obtained, and the number of operational taxonomic units for each sample was between 165 and 285. The alpha diversity of the QA and BA samples was higher, and a total of two phyla, eight classes, 12 orders, 15 families, and 16 genera were detected. At the genus level, significant differences were noted in the dominant genera among the samples, with three genera being shared in all the samples. The dominant genus in QA was Erythrobasidium, while that in AQA, HA, and BA was Sporobolomyces, and that in WA was Alternaria, reaching a proportion of 16.50%. These results showed that the fungal community structure and diversity in QA and BA were high. The endophytes are of great importance to the plants, especially for protection, phytohormone and other phytochemical production, and nutrition. Therefore, this study may be significant with the industrial perspective of Artemisia species.

Skimmin Improves Insulin Resistance via Regulating the Metabolism of Glucose: In Vitro and In Vivo Models.

Skimmin is the major pharmacologically active component present in Hydrangea paniculata, in the traditional Chinese medicine as an anti-inflammatory agent, and its anti-inflammation and anti-diabetic effect has had been studied in previous studies. The metabolism of glucose plays an important role in the pathophysiology of diabetes. Therefore, it was identified as an important target for improving diabetic. Herein, we found that skimmin relieved the palmitic acid and high-fat and high sugar-induced insulin resistance. Furthermore, skimmin enhanced the glucose uptake via inhibiting reactive oxygen species (ROS) and reducing the level of inflammatory correlation factor. Meanwhile, skimmin reduced the glucose output by promoting PI3K/Akt signaling pathway and down-regulating the expression of glycogen synthase kinase-3ß (GSK3ß) and glucose-6-phosphatase (G6Pase). In conclusion, skimmin can improve the insulin resistance by increasing glucose uptake and decreasing glucose output in vitro and in vivo.

One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.

PURPOSE: To compare selection for fluoroquinolone-resistant bacteria between 1-day and 3-day application of topical moxifloxacin 0.5%. SETTING: Department of Ophthalmology, Stanford University, Stanford, California, USA. METHODS: After investigative review board approval, patients scheduled for ocular surgery were randomized to receive topical moxifloxacin 0.5% drops 4 times a day for 1 day or 3 days preoperatively. Conjunctival cultures were obtained at baseline and after antibiotic application. Bacteria were identified and tested for resistance to a battery of antibiotic agents using the Kirby-Bauer disk-diffusion method. The differences in resistance distributions for the most commonly isolated bacteria between baseline (T0) and after antibiotic administration (T1) were compared between the 2 treatment groups. RESULTS: Coagulase-negative Staphylococcus (CNS) were the most common bacteria isolated at T0 and T1. At T0, the proportion of CNS isolated in the 1-day group (n = 63) that was resistant to fluoroquinolones ranged from 4% to 22% depending on the antibiotic agent tested. After 1-day treatment with moxifloxacin, the percentage of resistant bacteria increased significantly (range 13% to 67%) for all fluoroquinolones except gatifloxacin (P<.05). Resistance to gentamicin and tobramycin also increased significantly. However, patients treated for 3 days (n = 57) showed no differences in bacterial resistance rates to any antibiotic agent tested. CONCLUSION: Prophylactic topical moxifloxacin 0.5% treatment starting 1 day before ocular surgery resulted in a significant increase in fluoroquinolone-resistant bacteria, while a 3-day antibiotic regimen did not select for resistant organisms.

Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria.

PURPOSE: Compare the efficacy of a 1-day versus 3-day application of topical 0.5% moxifloxacin in reducing preoperative conjunctival bacteria. METHODS: Following IRB approval, patients (n = 144) scheduled for ocular surgery between 2004 and 2005 were recruited and randomized to receive topical 0.5% moxifloxacin drops four times a day for either 1 day (n = 63) or 3 days (n = 57) prior to surgery. Conjunctival cultures were obtained at baseline (T0), after application of antibiotic (T1), following povidone-iodine and additional antibiotic applications immediately before surgery (T2), and after surgery (T3). Cultures were inoculated onto blood and chocolate agar plates and in thioglycolate broth, and then incubated at 37 degrees C for 10 days. Bacterial growth were isolated, identified, quantified, and compared. RESULTS: There were similar (P = 0.8435) rates of patients with positive thioglycolate cultures between the 1-day (79.37%) and 3-day groups (82.46%) at T0. At T1, T2, and T3, the number of eyes with positive cultures were again similar (1 day, 3 days, P value [T1: 34.9%, 35.1%, P = 0.8631; T2: 14.3%, 7%, P = 0.3245; T3: 7.9%, 3.5%, P = 0.5199]). No significant differences were found between the colony-forming units (CFU) of bacteria on solid agar media in 1-day and 3-day groups at any of the time points studied (P values: 0.1-0.8). Coagulase-negative Staphylococcus was the most commonly isolated (73.3% at baseline). CONCLUSIONS: In patients undergoing intraocular anterior segment surgery, 1-day and 3-day applications of topical 0.5% moxifloxacin appear to have similar efficacy in reducing perioperative conjunctival bacteria.